Company intelligence / Profile preview

Embecta

Parsippany, New Jersey, United Statesgo.embecta.com ↗

Ownership: Public · EMBC
Development stage: Commercial

Overview

Embecta is a global leader in diabetes care devices with a commercial portfolio focused on insulin injection products. The company manufactures approximately 8 billion pen needles and syringes annually for over 30 million people in more than 100 countries. It has recently advanced development of a proprietary patch pump for type 2 diabetes that has received FDA breakthrough device designation[1][3][6].

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Consumable Medical Devices

Financials

Market cap: $303.8M
Total revenue: $271.7M
Enterprise value: $1.6B

Beyond the preview

Go deeper on Embecta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embecta.

Explore the full profile